Literature DB >> 8419262

Prognostic value of p53 overexpression and c-Ki-ras gene mutations in colorectal cancer.

S M Bell1, N Scott, D Cross, P Sagar, F A Lewis, G E Blair, G R Taylor, M F Dixon, P Quirke.   

Abstract

BACKGROUND: Mutations in Ki-ras codon 12 and the p53 gene are common abnormalities in colorectal cancer. The occurrence of p53 overexpression and/or Ki-ras codon 12 mutations were analyzed in 100 colorectal adenomas to determine if they were related to patient survival.
METHODS: p53 overexpression was identified by immunohistochemistry, and Ki-ras codon 12 mutations were detected using the polymerase chain reaction and a restriction enzyme digestion method.
RESULTS: p53 overexpression was identified in 45% of tumors, with a higher frequency identified in DNA aneuploid and left-sided tumors than in DNA diploid and right-sided tumors. Mutations in Ki-ras codon 12 were identified in 24% of carcinomas. Individually, mutations in Ki-ras codon 12 or p53 overexpression were not prognostic indicators of survival. However, a statistically significant difference in survival was identified when these two oncogenic abnormalities were analyzed together. The median survival of patients whose tumors contained both oncogenic abnormalities was less than half of that of patients with either alteration alone or without either abnormality.
CONCLUSIONS: Screening for multiple genetic abnormalities in colorectal cancers excised at surgery may prove to be a useful tool in determining prognosis.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8419262     DOI: 10.1016/0016-5085(93)90835-z

Source DB:  PubMed          Journal:  Gastroenterology        ISSN: 0016-5085            Impact factor:   22.682


  52 in total

Review 1.  Demystified ... oncogenes.

Authors:  Y L Wallis; F Macdonald
Journal:  Mol Pathol       Date:  1999-04

2.  Prognostic value of immunohistochemistry for p53 in primary soft-tissue sarcomas: a multivariate analysis of five antibodies.

Authors:  P Würl; H Taubert; A Meye; D Berger; C Lautenschläger; H J Holzhausen; H Schmidt; H Kalthoff; F W Rath; H Dralle
Journal:  J Cancer Res Clin Oncol       Date:  1997       Impact factor: 4.553

3.  Imunoexpression of Ki-67 and p53 in rectal cancer tissue after treatment with neoadjuvant chemoradiation.

Authors:  Nara Rosana Andrade; Celina Tizuko Fujiyama Oshima; Thiago Simão Gomes; Ricardo Artigiani Neto; Nora Manoukian Forones
Journal:  J Gastrointest Cancer       Date:  2011-03

4.  p53 expression in carcinoma of the cervix.

Authors:  C R Hunt; R J Hale; C H Buckley; J Hunt
Journal:  J Clin Pathol       Date:  1996-12       Impact factor: 3.411

5.  Associations of Ki-ras proto-oncogene mutation and p53 gene overexpression in sporadic colorectal adenomas with demographic and clinicopathologic characteristics.

Authors:  Janine G Einspahr; Maria Elena Martinez; Ruiyun Jiang; Chiu-Hsieh Hsu; Asif Rashid; Achyut K Bhattacharrya; Dennis J Ahnen; Elizabeth T Jacobs; P Scott Houlihan; C Renee Webb; David S Alberts; Stanley R Hamilton
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2006-08       Impact factor: 4.254

6.  KRAS status and clinical outcome in metastatic colorectal cancer patients treated with first-line FOLFOX chemotherapy.

Authors:  Neelesh Sharma; Maher Saifo; Ila R Tamaskar; Ramkumar Bhuvaneswari; Terry Mashtare; Marwan Fakih
Journal:  J Gastrointest Oncol       Date:  2010-12

7.  Prognostic significance of p53 expression in relation to DNA ploidy in colorectal adenocarcinoma.

Authors:  X F Sun; J M Carstensen; O Stål; H Zhang; E Nilsson; R Sjödahl; B Nordenskjöld
Journal:  Virchows Arch A Pathol Anat Histopathol       Date:  1993

8.  p53 mutations in gastric and colorectal cancers in Texas Hispanics versus Anglos.

Authors:  B G Schneider; S G Hilsenbeck; C H Hensel; V Pekkel; C H Shelton; H A Rodríguez-Martínez; M E Gutiérrez-Díaz; D R Pulitzer; D C Allred
Journal:  Virchows Arch       Date:  1994       Impact factor: 4.064

9.  Synchronous colon carcinomas: molecular-genetic evidence for multicentricity.

Authors:  R J Koness; T C King; S Schechter; S F McLean; C Lodowsky; H J Wanebo
Journal:  Ann Surg Oncol       Date:  1996-03       Impact factor: 5.344

10.  Mutational profiling of the RAS, PI3K, MET and b-catenin pathways in cancer of unknown primary: a retrospective study of the Hellenic Cooperative Oncology Group.

Authors:  G Pentheroudakis; E A Kotteas; V Kotoula; K Papadopoulou; E Charalambous; A Cervantes; T Ciuleanu; G Fountzilas; N Pavlidis
Journal:  Clin Exp Metastasis       Date:  2014-07-05       Impact factor: 5.150

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.